HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST - HYBRID FC FUSION PROTEIN
摘要
<p>The present invention relates to a fusion protein resulting from the coupling of a human interleukin-1 receptor antagonist and hybrid Fc. More specifically, provided is a fusion protein in which a human interleukin-1 receptor antagonist is coupled to a human immunoglobulin (Ig) hybrid Fc fragment. The hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the fusion protein. The pharmaceutical composition of the present invention can be used for the treatment of autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease (e.g. Crohn's disease and ulcerative bowel disease), psoriasis, diabetes and the like. The fusion protein of the present invention can be expected to be usable in the development of new autoimmune-disease drugs which maintain far better efficacy and have fewer side effects than existing autoimmune-disease drugs.</p>